Skip to content

IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection

Identification of Ovarian Malignancy With Ultrasonography Based Criteria (IOTA) and Serum CA 125

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06977334
Acronym
IOTA-CA125
Enrollment
64
Registered
2025-05-18
Start date
2022-01-01
Completion date
2022-12-31
Last updated
2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer, Ovarian Carcinoma, Ovarian Neoplasms

Keywords

IOTA, CA 125, Ultrasonography, Ovarian malignancy

Brief summary

This cross-sectional analytic study assessed the diagnostic accuracy of IOTA Simple Rules versus serum CA 125 in women with adnexal masses undergoing surgery. Eighty-two percent of tumors were classifiable by IOTA criteria; CA 125 cut-offs of 35, 70, and 105 U/mL were evaluated against histopathology gold standard.

Detailed description

All women admitted to the Department of Obstetrics and Gynecology and assigned for the surgery of adnexal mass were enrolled in the study. After written informed consent, the clinical proforma was filled up. Data collection regarding age, current or previous hormonal contraception, menopausal status and family history of breast or ovarian cancer, clinical presentation. Participants were scheduled for ultrasound evaluation done according to IOTA simple rules (five malignant features and five benign features) and peripheral blood was collected for tumor marker serum CA125 measurement. During ultrasonographic examination, the morphology of the adnexal masses was characterized using 2D real-time and color Doppler ultrasound. Adnexal masses were described according to origin (ovarian/extra ovarian); position (right/left/bilateral); number of lesions; type of lesions (unilocular/unilocular - solid/multilocular/multilocular - solid); size; volume; intracystic fluid echogenicity; number of locations; presence and size of septations; presence, number, size of solid papillary projections; largest solid component; presence / absent of ascites. These parameters are used as designation according to IOTA Group. For the sample of CA125, approximately 2 ml blood was collected and registered patient's hospital number, then the selected reagent was added to the sample and kept in a fully automated immunoassay system in the hospital laboratory where electrochemiluminescence Immunoassay method (ECLIA) is used for the analysis. Surgery was performed in the hospital and a biopsy was sent for the histopathology examination in the same hospital. Sensitivity, specificity, positive predictive value, and negative predictive values of CA125 and IOTA class were calculated. The correlation between CA 125 and IOTA simple rules was analyzed and compared with histopathological reports using the Pearson correlation method. The area under the receiver operating characteristic curve (AUC) was used to determine the point at which CA125 had the highest sensitivity and specificity in distinguishing histologically malignant from benign tumors.

Interventions

None listed

Sponsors

Maharajgunj Medical Campus
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* All age groups and parity with ovarian mass admitted for scheduled surgery.

Exclusion criteria

* Proven cases of ovarian malignancy * Ovarian mass in pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of IOTA Simple RulesAt surgery/histopathologyProportion of histologically malignant masses correctly identified by IOTA criteria.
Specificity of IOTA Simple RulesAt surgery/histopathologyProportion of histologically malignant masses correctly identified by IOTA criteria.
Sensitivity of Serum CA 125 (cut-off 35 U/mL)Preoperative blood drawProportion of malignant tumors with CA 125 \>35 U/mL.
Specificity of Serum CA 125 (cut-off 35 U/mL)Preoperative blood drawProportion of benign tumors with CA 125 ≤35 U/mL.
Area Under the ROC Curve for CA 125Preoperative blood draw vs histopathologyDiscriminatory performance of CA 125 at multiple cut-off points.

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026